ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) announced that Waterbury Pulmonary Associates Research has joined the pilot clinical study of Biomoda’s CyPath® diagnostic assay. Waterbury Pulmonary Associates Research is enrolling participants for the positive control group, patients diagnosed with lung cancer who have not yet started treatment. Based in Waterbury, CT, Waterbury Pulmonary Associates Research is the clinical research arm of a pulmonary and critical care practice.
